Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test

Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test

Background: Approximately 23% of myeloma patients have cytogenetic abnormalities which confer a significantly poorer prognosis, and therefore they are defined as “high-risk myeloma” (HRC+) patients. Objective: To estimate the economic impact of a large-scale use of the fluorescence in situ hybridiz...

Full description

Bibliographic Details
Main Authors: Rossella Bitonti, Federica Demma, Massimiliano Rea, Gianluca Furneri
Format: Article
Language:English
Published: AboutScience Srl 2022-11-01
Series:AboutOpen
Subjects:
Appropriateness
Cost
FISH
HRC
Myeloma
Triplets
Online Access:https://journals.aboutscience.eu/index.php/aboutopen/article/view/2447

Similar Items

Similar Items